The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
Combining a GLP-1 receptor agonist, to increase endogenous beta cell function, with exogenous insulin is a possible therapeutic option for the treatment of type 2 diabetes. Here, the authors show adding exenatide to basal insulin in early type 2 diabetes does not further enhance underlying pancreati...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-33867-9 |
| _version_ | 1798029780625391616 |
|---|---|
| author | Ravi Retnakaran Chang Ye Alexandra Emery Caroline K. Kramer Bernard Zinman |
| author_facet | Ravi Retnakaran Chang Ye Alexandra Emery Caroline K. Kramer Bernard Zinman |
| author_sort | Ravi Retnakaran |
| collection | DOAJ |
| description | Combining a GLP-1 receptor agonist, to increase endogenous beta cell function, with exogenous insulin is a possible therapeutic option for the treatment of type 2 diabetes. Here, the authors show adding exenatide to basal insulin in early type 2 diabetes does not further enhance underlying pancreatic beta-cell function or the capacity to achieve diabetes remission, but may yield on-treatment glycemic benefits. |
| first_indexed | 2024-04-11T19:30:56Z |
| format | Article |
| id | doaj.art-7dfbcc22d4e74f62a30ad39bc6fd1bfb |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-11T19:30:56Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-7dfbcc22d4e74f62a30ad39bc6fd1bfb2022-12-22T04:07:00ZengNature PortfolioNature Communications2041-17232022-10-0113111110.1038/s41467-022-33867-9The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trialRavi Retnakaran0Chang Ye1Alexandra Emery2Caroline K. Kramer3Bernard Zinman4Leadership Sinai Centre for Diabetes, Mount Sinai HospitalLeadership Sinai Centre for Diabetes, Mount Sinai HospitalLeadership Sinai Centre for Diabetes, Mount Sinai HospitalLeadership Sinai Centre for Diabetes, Mount Sinai HospitalLeadership Sinai Centre for Diabetes, Mount Sinai HospitalCombining a GLP-1 receptor agonist, to increase endogenous beta cell function, with exogenous insulin is a possible therapeutic option for the treatment of type 2 diabetes. Here, the authors show adding exenatide to basal insulin in early type 2 diabetes does not further enhance underlying pancreatic beta-cell function or the capacity to achieve diabetes remission, but may yield on-treatment glycemic benefits.https://doi.org/10.1038/s41467-022-33867-9 |
| spellingShingle | Ravi Retnakaran Chang Ye Alexandra Emery Caroline K. Kramer Bernard Zinman The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial Nature Communications |
| title | The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| title_full | The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| title_fullStr | The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| title_full_unstemmed | The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| title_short | The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| title_sort | metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial |
| url | https://doi.org/10.1038/s41467-022-33867-9 |
| work_keys_str_mv | AT raviretnakaran themetaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT changye themetaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT alexandraemery themetaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT carolinekkramer themetaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT bernardzinman themetaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT raviretnakaran metaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT changye metaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT alexandraemery metaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT carolinekkramer metaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial AT bernardzinman metaboliceffectsofaddingexenatidetobasalinsulintherapywhentargetingremissioninearlytype2diabetesinarandomizedclinicaltrial |